Strong U.S. demand and new product launches drive first-half sales in Human PharmaNet sales reach EUR 15.8 billion, led by JARDIANCE® and successful U.S. launchesPositive Phase III data for survodutide and pipeline progress strengthen long-term outlook
Boehringer Ingelheim reports first-half 2026 sales growth, driven by JARDIANCE® and new product ...
